Shots:

• The approval is based on REAL 1 study assessing Sogroya (10 mg/ 1.5 mL (6.7 mg/mL) vs PBO for 35wks. in adults patients with growth hormone deficiency
• The US FDA ahs approved the BLA of the therapy for the replacement of endogenous growth hormone in adults with GHD
• Sogroya is a prescription medicine containing GH and is used to treat adults who do not make enough growth hormone. Efficacy and safety in children are not known

­ Ref: Businessnewswire | Image: Businessnewswire